In a report released today, Judah Frommer from Morgan Stanley maintained a Sell rating on Galapagos (GLPG – Research Report), with a price ...
Shares of Galapagos NV (NASDAQ:GLPG – Get Free Report) have earned an average rating of “Strong Sell” from the nine analysts that are covering the firm, Marketbeat reports. Five investment analysts ...
Galapagos NV (NASDAQ:GLPG) received FDA's IND clearance to begin clinical studies in the US for their CD19 CAR-T program, GLPG5101. The company reported strong clinical data from the ATLANTA study ...
Galapagos NV (AMS:GLPG) shareholders should be happy to see the share price up 13% in the last week. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Five years have ...
Good day and thank you for standing by. Welcome to the Galapagos Full Year 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode ...
In trading on Tuesday, shares of Galapagos NV (Symbol: GLPG) crossed above their 200 day moving average of $27.07, changing hands as high as $27.48 per share. Galapagos NV shares are currently ...
In a report released on February 13, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG – Research Report), with a price target of $32.00. The company’s shares closed ...
Shares of Galapagos (NASDAQ:GLPG) (OTCPK:GLPGF) ended a four-day winning streak on Friday after Morgan Stanley downgraded the Belgian biotech, citing its decision to deprioritize its CAR-T therapy ...
Specialist bridge lender Hilco Real Estate Finance (HREF) has provided a £14.2m development exit loan to Torsion Group, a ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results